<DOC>
	<DOC>NCT00048555</DOC>
	<brief_summary>To determine what side effects and what clinical effect, if any, the administration of this investigational product, IDEC-114 in combination with Rituxan速 [Rituxan速 as a single agent is approved by the United States Food and Drug Administration (FDA) to treat patients with relapsed or refractory follicular NHL], has in this patient population.</brief_summary>
	<brief_title>Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Signed IRBapproved informed consent Greater than or equal to 18 years of age Proof of follicular lymphoma Progressive disease requiring treatment after at least 1 prior standard therapy Acceptable hematologic status, liver function, and renal function Patients of reproductive potential must agree to follow accepted birth control methods during treatment and for 3 months after completion of treatment No response to prior Rituxan速 or Rituxan速containing regimen Presence of CLL or CNS lymphoma Known history of HIV infection or AIDS Prior diagnosis of aggressive NHL or mantlecell lymphoma Serious nonmalignant disease Pregnant or currently breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>